title: Is a reduction of graft vessel disease by maximal treatment of hypercholesterolemia after heart transplantation possible?
authors.affiliation: Department of Cardiac Surgery, Munich-Bogenhausen, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Wenke
authors.forename: B
authors.initials: B
authors.lastname: Meiser
authors.forename: J
authors.initials: J
authors.lastname: Thiery
authors.forename: N
authors.initials: N
authors.lastname: Arndtz
authors.forename: W
authors.initials: W
authors.lastname: von Scheidt
authors.forename: D
authors.initials: D
authors.lastname: Seidel
authors.forename: B
authors.initials: B
authors.lastname: Reichart
mesh_terms: D000328:Adult; D003327:Coronary Disease / Q000517:prevention & control*; D016572:Cyclosporine / Q000097:blood; D005260:Female; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006084:Graft Rejection; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000628:therapy*; D008148:Lovastatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019821:Simvastatin
chemical_list: D016572:Cyclosporine; D008148:Lovastatin; D019821:Simvastatin